Feng Yuan

Feng Yuan

Auto-generated profile, based on publicly available information

Feng Yuan

Breast Cancer Center Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology, National Key Clinical Specialty Discipline Construction Program, Hubei Provincial Clinical Research Center for Breast Cancer, Wuhan Clinical Research Center for Breast Cancer Wuhan Hubei China

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications

18 January 2022 in Natural Resources Research
Verified
Journal Article
Closed access
PDF file
FDFanfan Dou
Fanfan Dou
HXHuaixue Xing
Huaixue Xing
XLXiaohui Li
Xiaohui Li
FYFeng Yuan
Feng Yuan
ZLZhitang Lu
Zhitang Lu
WGWeiya Ge
Weiya Ge



1 November 2012 in Journal of Applied Geophysics
Verified
Journal Article
Closed access
Gongwen WangGongwen Wang
Gongwen Wang
SZShouting Zhang
Shouting Zhang
CYChanghai Yan
Changhai Yan
GXGuoyan Xu
Guoyan Xu
Min MaMin Ma
Min Ma
YFYuan Feng
Yuan Feng

9 July 2025 in Journal of Cellular and Molecular Medicine
Verified
Journal Article
Open access
FYFeng Yuan
Feng Yuan
GLGai Liang
Gai Liang
QZQu Zhang
Qu Zhang
BLBo Luo
Bo Luo
JLJianhua Liu
Jianhua Liu
XWXinhong Wu
Xinhong Wu
Breast cancer is classified into multiple subtypes, including hormone receptor‐positive (oestrogen/progesterone receptor, ER/PR), HER2‐positive (human epidermal growth factor receptor 2), and triple‐negative breast cancer (TNBC). Among these, TNBC is more aggressive and susceptible to recurrence. The identification of novel TNBC‐specific markers is crucial for the development of advancing therapeutic approaches for this subtype. In our study, firstly we integrated single‐cell RNA sequencing data from more than 260,000 cells from previously published breast cancer datasets with ER‐positive, HER2‐positive and TNBC samples, determined the cell types based on the marker genes and identified the differentially expressed genes across various cell types between TNBC and ER/HER2‐positive cancers using pseudobulk analysis. Additionally, we conducted gene set enrichment analysis (GSEA) with the differentially expressed genes and identified 8 pathways which are consistent between the comparisons of TNBC/ER‐positive and TNBC/HER2‐positive. Furthermore, we found the shared gene, LARP6 (La Ribonucleoprotein 6) was significantly upregulated in TNBC compared to ER and HER2‐positive breast cancers. Also, the result from survival analysis revealed that the high LARP6 level significantly affected patient survival. At last, we found LARP6 was highly expressed in the TNBC cell line, and knockdown of LARP6 reduced cell proliferation, which was associated with the cell cycle alterations as determined by TriCycle analysis. Immune infiltration analysis further revealed that LARP6 expression correlates with distinct immune cell populations in the tumour microenvironment, suggesting its role beyond cancer cell intrinsic functions.